Page 70 of 73
Animal Health News & Notes for November 11, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for November 11, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Aventis Animal Nutrition reported nine-month sales of 421 million euros ($370 million) compared with 411 million in the year-ago period, an increase of 2%, due to ongoing price pressure. (company press release) > Virbac Corporation announced results of operations for the third quarter and nine months ended September 30, 2000. For the 2000 third quarter, net sales rose 11.5% to $14.3 million. Net income increased 25% $1.0 million. The results for this quarter are the best in the company’s history. For the nine months ended September 30, 2000, net sales rose 3% to $41.5 million. Net income climbed 128% to $2.8 million in the first nine months of 1999. Results for the nine months ended September 30, 1999, are presented as if Virbac, Inc., and Agri-Nutrition Group Limited, which were merged on March 5, 1999, were combined for the entire first nine months of 1999. Among the highlights of the third quarter, the company signed a licensing agreement for four pharmaceutical products currently under development for the pet and companion animal market. The company also licensed two of its equine products to Pfizer, Inc., for significant initial and milestone payments, as well as royalties based on sales and
;
November 11, 2000
Animal Health News & Notes for November 3, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for November 3, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Novo Nordisk reported that operating profit for Novozymes (Enzyme Business) increased by 24% to DKK 585 million ($69 million) compared with DKK 472 million ($56 million) for the nine months of 1999. Sales increased by 13% to DKK 3,738 million ($440 million) from DKK 3,313 million ($390 million) in the same period of 1999. The animal feed enzyme sales continued to perform strongly with a 29% increase. Ronozyme P has been introduced on the US market at the beginning of the fourth quarter. (PRNewswire) > Pilgrim’s Pride Corporation announced net income of $11.3 million for the fourth fiscal quarter ended September 30, 2000, a decrease of 31.1%, compared to the prior year’s fourth quarter of $16.4 million. The Company also announced net sales of $379.3 million for the fourth fiscal quarter, a 9.2% increase, compared to the $347.3 million for the same period last year. For fiscal 2000, the Company reported net income of $52.3 million, a decrease of 19.8%, compared to the prior fiscal year’s net income of $65.3 million. Net sales for fiscal 2000 were a record high of $1.5 billion, a 10.5% increase, compared to $1.4 billion for the same period last year. The
;
November 3, 2000
Animal Health News & Notes for October 27, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for October 27, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Pfizer reported that third quarter sales of Animal Health were $208 million, down 38% from the comparable period in 1999. The decline in sales reflected the size of the initial distribution of Revolution requested by veterinarians in the U.S. in the third quarter of 1999, competitive pressures on key brands, continuing weakness in U.S. and European livestock markets, and the negative impact of foreign exchange. On October 2, 2000, Pfizer announced that it was selling its medicinal feed additives business to Phibro Animal Health. (PRNewswire, company news) > Novartis reported that nine month 2000 sales in its Animal Health division were CHF 789 million ($455 million), an increase of 5% over the comparable period in 1999. The positive trend in the Farm Animal business continued, led by the anti-infective tiamulin, which posted high double-digit growth. As expected, the companion animal business had to contend with strong competition in the flea and heartworm treatment segment, constraining sales of Sentinel (combined flea, intestinal and heartworm treatment for dogs), Program (flea prevention) and Interceptor (heartworm treatment). As expected, sales development remained sluggish in the US and reflected the earlier start to the fall sales campaign in 1999. The trend was positive
;
October 27, 2000
Animal Health News & Notes for October 20, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for October 20, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Eli Lilly reported that worldwide sales for Elanco in the third quarter were $164.4 million, an increase of 10% when compared with the third quarter of 1999. Excluding the effect of exchange rates, sales grew by 13% for the quarter. (PRNewswire) > IBP reported third quarter 2000 net earnings totaled $83.9 million compared to $96.6 million or before a $13.8 million nonrecurring reduction of income tax expense during the same period in 1999. Third quarter sales grew 9% to $4.2 billion versus $3.8 billion in 1999. Prior year results have been restated to reflect the acquisition of Corporate Brand Foods America, Inc. (CBFA), which was accounted for as a pooling of interests. Year-to-date earnings, before unusual and nonrecurring items, totaled $203 million in 2000 compared to $231 million during the first nine months of 1999. Net sales for the first three quarters totaled $12.2 billion, 15% higher than the $10.6 billion recorded last year. (company press release) **************************************************************** Company News Releases > Pharmacia & Upjohn announced the introduction of Neomix AG 325 Feed Medication, for treatment against E. coli in swine. The product permits flexible feed inclusion to maintain an effective dose. (DVM Newsmagazine) > Ralston Purina has
;
October 20, 2000
Animal Health News & Notes for October 13, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for October 13, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > IDEXX Laboratories, Inc. reported net income of $9.3 million for the quarter ended September 30, 2000, compared to net income of $8.4 million for the same period in the prior year. Revenues for the third quarter increased to $90.4 million from $86.4 million for the third quarter of 1999. For the nine months ended September 30, 2000, net income increased to $26.8 million from $23.7 million for the first nine months of 1999. Revenues for the nine months ended September 30, 2000, increased to $274.8 million from $267.6 million in the same period in 1999. (company press release) **************************************************************** Company News Releases > SLIL Biomedical Corp. announced that it has signed an agreement with Elanco Animal Health. The deal is specifically for veterinary and other animal health indications of SLIL’s drug discovery pipeline. According to SLIL’s President/CEO, SLIL’s drug discovery program has generated 16 lead compounds for animal health indications. SLIL’s efforts have been aimed primarily at human cancer indications. However, several of its novel compounds have also shown promise as therapeutic agents in animal health. (PRNewswire) > Heska Corporation announced that it has been named to Deloitte and Touche’s prestigious “Fast 50” program for Colorado, a ranking
;
October 13, 2000
Animal Health News & Notes for October 6, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for October 6, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company News Releases > Pfizer agreed to sell the feed-additive products of its Animal Health Group to Philipp Brothers Chemicals Inc.’s Phibro Animal Health unit. Philipp Brothers, along with New York investment firm Palladium Equity Partners, issued a press release disclosing the purchase price of $155 million for Pfizer’s feed-additive products. The transaction includes its Aviax, Banminth, Bloat Guard, CLTC, Coxistac, Mecadox, Neo-Terramycin, OXTC, Rumatel, Stafac and Terramycin product lines. The companies said the transaction is expected to close by the end of the year. (Dow Jones) > DirectAg.com announced that Schering-Plough Animal Health Corp. has joined as an e-business partner. Schering-Plough is the most recent industry leader to join DirectAg.com’s animal health community. Through this partnership, producers will be able to purchase Schering-Plough vaccines, insecticides and Ralgro Implants through DirectAg.com. DirectAg.com will also link directly to Schering-Plough’s on-line resources for livestock producers. (PRNewswire) > PETCO Animal Supplies, Inc. announced that it has completed the previously announced merger of the company with BD Recapitalization Corp. In the merger, each issued and outstanding share of PETCO common stock was cancelled and converted automatically into the right to receive $22.00 in cash, without interest or any other payment thereon, with the following exceptions: certain
;
October 6, 2000
Animal Health News & Notes for September 29, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for September 29, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Neogen Corporation announced that its revenues for the first quarter, which ended Aug. 31, were 52% higher than the previous fiscal year’s first quarter. Neogen reported revenues of $8.1 million for the first quarter of the 2001 fiscal year, compared with $5.3 million for the same period last year. Neogen’s first quarter revenues were bolstered by strong internal growth in addition to the acquisitions of Acumedia Manufacturers in February 2000 and AmVet Pharmaceuticals in June 2000. Of the 52% increase in the quarter-to-quarter comparison with last year’s first quarter, 23% can be attributed to internal growth, and the balance to new revenue sources. Animal Safety Division sales were up 39% from the previous year. (PRNewswire) > PetQuarters, Inc. announced the financial results for the fiscal year ended June 30, 2000. Net sales for the year were $13.7 million as compared to $262,470 from the prior year. The Company’s gross profit margin was a positive $4.3 million or 31%. The reported numbers include twelve months of Internet revenues and eleven months of catalog revenues because the Company closed on the acquisition of its catalog operation in August of 1999. The loss for fiscal year 2000 of $14.7 million included
;
September 29, 2000
Animal Health News & Notes for September 22, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for September 22, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Alcide Corporation announced net sales and earnings for its first fiscal quarter which ended Aug. 31, 2000. Net sales of $4.2 million for the quarter ending Aug. 31, 2000 were the highest for any quarter in Alcide’s history and were 59% higher than for the first quarter last year. Sales of Sanova food antimicrobial to the poultry industry totaled $1.7 million, an increase of $1.3 million compared to the first fiscal quarter last year, as this new Alcide business continued to expand rapidly. At the end of the quarter 19 plants representing 11% of the total U.S. poultry market, were utilizing the Sanova System to improve the quality of their product. In addition to the 19 plants now operational, there are 4 Sanova Systems in various stages of installation and scheduled to start within the next 30 days and 4 additional plants have contracted for Sanova installation in the future, resulting in a total of 27 plants under contract. (Business Wire) **************************************************************** Company News Releases > Pfizer announced the retirement of Brian Barrett as Vice President, Pfizer Inc, and President of the Animal Health Group. Mr. Barrett will retire at the end of February 2001, following a distinguished
;
September 22, 2000
Animal Health News & Notes for September 15, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for September 15, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company News Releases > Intervet introduced PRISIM (Performance Report for Integrating Solutions in Management), a program providing feedlot managers with a comprehensive performance analysis tool. The program includes 20 parameters that allow feedlot managers to predict cattle growth and performance. The program will be licensed to Intervet feedlot customers, beef industry consultants and nutritionists. (Feedstuffs) > Merial announced that it has received approvals from the EPA to market FRONTLINE Plus for Dogs and FRONTLINE Plus for Cats in the United States. These new products combine an adulticide (fipronil) and insect growth regulator (s-methoprene) for complete flea control and broad-spectrum tick protection for dogs and cats. Like other FRONTLINE brand products, FRONTLINE Plus is a spot-on flea and tick preventive. Merial intends to introduce FRONTLINE Plus into other countries around the world as soon as possible, subject to local regulatory approvals. (company website) > Applied Molecular Evolution, Inc. announced that it has granted a non-exclusive sublicense to IDEXX Laboratories, Inc. for Applied Molecular Evolution’s (AME’s) Kauffman patents for directed evolution. IDEXX plans to use the Kauffman patents to develop diagnostic applications. The Kauffman patent family comprises six issued U.S. patents with claims covering methods of stochastically generating proteins, which AME believes is required
;
September 15, 2000
Animal Health News & Notes for September 8, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for September 8, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Vetoquinol reported sales of FF 633 million ($97 million) for 1999, an increase of 27% over 1998. Revenue was boosted by the group’s acquisition of Canadian J. Webster Laboratories in spring 1999. (Animal Pharm) ***************************************************************** Company News Releases > Brakke Consulting Inc. has entered into a Strategic Consulting Alliance with Zoaport, Inc. Zoaport is developing a suite of integrated, Internet based solutions for the animal health industry focused on information aggregation, information exchange, and commerce. Zoaport has assembled a world-class management team, advisory board, and set of financial backers, including Atlanta based iXL Ventures. Unique features of the Zoaport offering include comprehensive information delivery, virtual private marketplaces, virtual communities, and mobile access. Brakke Consulting will contribute its knowledge of the animal health industry to the expertise Zoaport has in the fields of information technology, e-commerce, and the Internet. (company press release) > Neogen Corporation announced that it has completed the acquisition of Squire Laboratories, Inc., and 15 veterinary products produced by the company. Neogen will continue to market the products under the Squire Laboratories label. The terms of the acquisition were approximately $1.0 million in cash. Neogen anticipates sales of Squire products will be approximately $1.0 million in
;
September 8, 2000
Animal Health News & Notes for September 1, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for September 1, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Pharmacia reported that animal health sales in the second quarter 2000 reached $108 million, an increase of 9% over the comparable period last year. Sales of Naxcel/Excenel and Licomix/Lincospectin were key drivers in the sales increase. Sales for the first half of 2000 were $208 million, an increase of 12% over 1999. (Animal Pharm) > Virbac S.A. reported provisional sales of FF 1,040 million ($150 million) for the first half of 2000, an increase of 18% over the comparable period in 1999. On a comparable basis, sales increased 14.4% over 1999. Sales of both companion animal and livestock products helped drive growth. (Animal Pharm, company website) > Boehringer Ingelheim reported sales for the first half of 2000 for the Animal Health business grew by 15% to 137 million Euro ($130 million). (company website) > Alpharma reported sales for the first half of 2000 for its Animal Health Division (AHD) were $114 million, up 51% over the comparable period in 1999. Sales for the second quarter 2000 were $73 million, an increase of 107% over the comparable period in 1999. AHD revenues increased due to acquisitions, primarily Alpharma’s acquisition of the medicated feed additive business of Roche on May
;
September 1, 2000
Animal Health News & Notes for August 25, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for August 25, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Novartis reported sales for the first half of 2000 were CHF 514 million ($312 million), an increase of 11% over the comparable period in 1999. Operating income declined 30% to CHF 66 million ($40 million). Sales were increased by dynamic growth in the Farm Animal business in Europe, Latin America and Asia, as well as the Vericore acquisition completed in January 2000. These gains were offset by strong competition in the US flea and heartworm business. In response to the challenging environment in the US market, Novartis Animal Health has significantly increased its US sales force. (company website) > PETsMART, Inc. announced financial results for its second fiscal quarter ended July 30, 2000. Net sales for the second quarter were $538.6 million, an increase of 4.5% over the $515.6 million reported for the same period last year, while North American comparable store sales for the quarter increased 1.2%. The Company reported second quarter net income of $6.5 million excluding the equity loss in PETsMART.com. That compares with second quarter 1999 net income of $6.6 million excluding the equity loss on PETsMART.com and the operating loss from the United Kingdom subsidiary. Including the $15.4 million of additional funding for
;
August 25, 2000
Animal Health News & Notes for August 21, 2000 – 1st Anniversary Edition
printer friendly version **************************************************************** Brakke Consulting’s Animal Health News & Notes for August 21, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** ANIMAL HEALTH NEWS & NOTES MARKS ONE-YEAR ANNIVERSARY This week marks the one-year anniversary of Brakke Consulting’s weekly electronic newsletter, “Animal Health News & Notes.” In the intervening weeks, our subscriber list has grown from under 200 addresses to over 1,300. Our readership encompasses all aspects of the animal health industry: from manufacturers of pharmaceuticals, biologicals, and pet products; to veterinary distributors; to government agencies and industry organizations; to the new realm of “dot-coms”. Newsletter recipients range from CEO’s to field sales representatives, and hail from dozens of countries around the world. We are proud to be a leading source of timely news about the animal health industry. We hope that you find our newsletter useful, and that you will continue to pass it on to friends and colleagues within the industry. ******************************************************************* BRAKKE CONSULTING, INC. Serving the Worldwide Animal Health and Pet Care Industries Providing a complete range of consulting services, including: > General Management Consulting > Technology Market Evaluation > Technology Transfer, Licensing, and Acquisition > Mergers, Acquisitions, Divestitures > Industry Information and Market Research > Executive and Managerial Search > Marketing and Communications Audits > Veterinary Practice Management
;
August 21, 2000
Animal Health News & Notes for August 18, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for August 18, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Bayer reported that sales of the Animal Health Business Group rose significantly in the first half of 2000. Its strong performance in the U.S. market in particular, led to a 17% boost in revenues. In China, a new facility for the production of veterinary pharmaceuticals and feed additives came on stream as part of Bayer’s strategy to expand its business in that country. (company website) > Synbiotics Corporation reported results for the second quarter ended June 30, 2000. Revenues for the quarter were $8.8 million, an increase of 4% compared to the second quarter of 1999. Net loss for the quarter was ($1.4 million), as compared to a profit of $473,000 for the year-ago quarter. Net income reflects a previously announced, non-cash after tax charge of ($583,000) related to a re-financing of the company’s debt facilities in April 2000. Sales reflected strong growth of Synbiotics Animal Health’s instrumentation products, which increased by 159% to $625,000 in the quarter, increases in diagnostic sales at Synbiotics-Europe, and the acquisition of the poultry diagnostics business of Kirkegaard and Perry Laboratories. Partially offsetting these increases were a decline in diagnostic sales to US distributors, erosion of ethical and OTC vaccine sales, and
;
August 18, 2000
Animal Health News & Notes for August 11, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for August 11, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Destron Fearing reported results for the third quarter ended June 30, 2000. Net sales were $4.2 million, compared with $5.3 million in the year-ago period. Net income was $404,000 compared with $1.3 million in 1999. In the third quarter, sales of electronic products declined 33% from the year-ago period, but remained at record levels through the first nine months of this fiscal year. Sale of visual products in the third quarter increased 15% over last year. (company press release) ***************************************************************** Company News Releases > Boehringer Ingelheim Vetmedica, Inc. (BIV) announced that a permanent injunction was issued by the United States District Court, District of New Jersey, against Schering-Plough Corporation’s Animal Health Division in connection with a patent infringement suit brought by BIV against Schering. BIV alleged in its lawsuit that Schering had infringed BIV’s patent covering the growth and manufacture of the Porcine Respiratory and Reproductive Syndrome (PRRS) virus used in BIV’s product lines of Ingelvac PRRS and ReproCyc PRRS swine vaccines. Earlier this year, a jury in Newark NJ heard the case and determined that Schering’s manufacture of its Prime-Pac PRRS vaccine does indeed infringe the BIV patent and that the patent is valid. The order issued
;
August 11, 2000
Animal Health News & Notes for August 4, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for August 4, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Central Garden & Pet Company announced financial results for the fiscal third quarter ended June 24, 2000. Net sales for the fiscal third quarter were $453.8 million compared to $529.1 million in the fiscal 1999 third quarter. Net income for the fiscal third quarter was $12.9 million compared with net income of $13.7 million in the comparable 1999 quarter. Net sales for the first nine months of fiscal 2000 were $1.1billion compared with $1.2 billion in the comparable 1999 period. Net income for the first nine months of fiscal 2000 was $18.5 million compared with net income of $28.8 million in the comparable 1999 period. (Business Wire) > Virbac Corporation announced that for the three months ended June 30, 2000, income before taxes increased 71% to $841,000 on net sales of $13.8 million, compared with income before taxes of $493,000 on net sales of $14.4 million in 1999. For the six months ended June 30, 2000, income before taxes increased 381% to $1.8 million on net sales of $27.1 million. Results for the six months ended June 30, 1999, are presented on an equivalent basis as if Virbac, Inc. and Agri-Nutrition Group Limited, which were merged on March
;
August 4, 2000
Animal Health News & Notes for July 28, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for July 28, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Pfizer reported that first-half 2000 sales of Animal Health were down by 6% to $553 million, reflecting the negative impact of foreign exchange, continuing weakness in U.S. and European livestock markets and the decision of the European Commission to ban certain antibiotic feed additives, including the Pfizer product virginiamycin, in the European Union after June 30th of last year. Sales for the second quarter 2000 were $287 million, down 5% from 1999. (PRNewswire) > Schering-Plough reported that worldwide sales of animal health products in the second quarter rose 1% (6% when foreign exchange is excluded) and totaled $174 million. First-half sales of animal health products increased 2% in the 2000 first half and totaled $332 million. (PRNewswire) > Aventis reported sales for Aventis Animal Nutrition during the first 6 months 2000 were $267 million (euro 280 million), compared to $270 million (euro 284 million) for the same period last year. Second quarter sales were $135 million (euro 142 million), flat compared to the second quarter 1999. Volumes of methionine and Vitamin A were sharply higher than last year, with strong growth recorded in the Asia-Pacific market in particular. However, these gains were offset by continued weakness in vitamin
;
July 28, 2000
Animal Health News & Notes for July 21, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for July 21, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > Elanco reported worldwide sales of animal health products in the second quarter were $151.3 million, an increase of 9% when compared with the second quarter of 1999. Excluding the effect of exchange rates, sales grew by 12% for the quarter. Paylean was launched in early July as a new swine feed ingredient that directs nutrients to increase the amount of quality meat in high-value cuts and improves production efficiencies. (PRNewswire) > Colgate-Palmolive reported that sales at Hill’s Pet Nutrition for the second quarter 2000 increased 4% on unit volume increases of 6%. Market shares have increased nationally in both the veterinary and specialty pet channels. Strong veterinarian endorsements, higher sales from Science Diet Feline Hairball Control and its lifestage variants, and effective national selling programs all benefited domestic growth and market shares in the quarter. Hill’s-International grew strongly in all regions. (Business Wire) > IDEXX Laboratories, Inc. reported net income of $9.5 million for the quarter ended June 30, 2000, compared to net income of $8.0 million for the same period in the prior year. Revenues for the second quarter increased to $93.6 million from $91.5 million for the second quarter of 1999. IDEXX also announced that Lou
;
July 21, 2000
Animal Health News & Notes for July 14, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for July 14, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company News Releases > Schering-Plough Corporation announced that it has signed a definitive agreement with Novartis Pharmaceuticals Corporation to purchase Novartis’ research and office facility located in Summit, N.J. Financial terms of the agreement are not being disclosed. The research and development, laboratory and office complex totals approximately 2 million square feet. Subject to certain terms and conditions being met, it is expected that the transaction will close in the fourth quarter. (PRNewswire) > Novartis Animal Health announced that it has entered an agreement with PetPlace.com to develop and publish a Drug Reference Library on PetPlace.com’s pet health resource website. Sponsored by Novartis, the Drug Reference Library will be operable in the fall and will benefit veterinarians and pet owners by providing them with accurate online pet medical information to ensure the best possible pet care. Use of the Drug Reference Library will be free of charge. (company press release) > As a clarification to a previously reported item regarding the closure of Aventis’ Virogenetics Corporation facility in New York: the Virogenetics group has moved to the Aventis facility in Toronto, Canada. Merial remains committed to the core development activities of Virogenetics, which have developed several groundbreaking vaccines. (company information) > Synbiotics
;
July 14, 2000
Animal Health News & Notes for July 7, 2000
**************************************************************** Brakke Consulting’s Animal Health News & Notes for July 7, 2000 Copyright © Brakke Consulting, Inc. **************************************************************** Company Earnings Releases > ***************************************************************** Company News Releases > Merial, in partnership with the veterinary diagnostics company Synbiotics and the University of Bristol, UK, has opened one of the first laboratories in the world to use the most advanced DNA testing methods to identify microbes transmitted by ticks, fleas, mosquitoes and other arthropods as part of a diagnostic and research service for veterinarians. The group stressed the importance of improving knowledge about the prevalence, epidemiology and disease potential for arthropod-transmitted infections in Europe, particularly with regard to multi-infections. (Animal Pharm) > Heska Corporation announced that it has launched its new Web site. The new site was created to expand Heska’s on-line presence to include e-commerce capabilities targeted at veterinarians for instant access to Heska’s broad range of companion animal health products. The newly designed Web site was created primarily for three audiences: customers in the veterinary market, companion animal enthusiasts seeking selected animal health information and those interested in general corporate information. (PRNewswire) > Roche and Novo Nordisk have agreed to a global strategic alliance for enzymes for animal feed. Within this alliance Novo Nordisk will provide its know-how in basic research, product development and production, while Roche will contribute its expertise
;
July 7, 2000
Page 70 of 73
English 
Portuguese 
Japanese 
Chinese